Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I. Thielen FW, et al. Among authors: riemsma r. Pharmacoeconomics. 2019 Aug;37(8):975-984. doi: 10.1007/s40273-018-0740-4. Pharmacoeconomics. 2019. PMID: 30547368 Free PMC article. Review.
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: riemsma r. Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Pharmacoeconomics. 2019. PMID: 30194622 Free PMC article. Review.
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ. Blommestein HM, et al. Among authors: riemsma r. Pharmacoeconomics. 2016 Jan;34(1):23-31. doi: 10.1007/s40273-015-0318-3. Pharmacoeconomics. 2016. PMID: 26314282 Free PMC article.
Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
Riemsma R, Corro Ramos I, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, Duffy S, Worthy G, Al M, Severens J, Kleijnen J. Riemsma R, et al. Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. doi: 10.3310/hta20170. Health Technol Assess. 2016. PMID: 26933827 Free PMC article. Review.
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N, Büyükkaramikli N, Penton H, Riemsma R, Wetzelaer P, Huertas Carrera V, Swift S, Drachen T, Raatz H, Ryder S, Shah D, Buksnys T, Worthy G, Duffy S, Al M, Kleijnen J. Armstrong N, et al. Among authors: riemsma r. Health Technol Assess. 2020 Oct;24(51):1-220. doi: 10.3310/hta24510. Health Technol Assess. 2020. PMID: 33108266 Free PMC article.
Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".
Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA. Ramaekers BLT, et al. Among authors: riemsma r. Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3. Pharmacoeconomics. 2017. PMID: 28391508 No abstract available.
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Among authors: riemsma r. Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Pharmacoeconomics. 2017. PMID: 28656543 Free PMC article. Review.
91 results